Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Expected outcomes of therapy

9 evidence topics · 8 sources

Summary: expected outcomes

STRIDE-II sets clinical remission and endoscopic healing as long-term treatment targets, adds absence of disability and restoration of quality of life, and sets symptomatic relief and normalization of serum and fecal markers as short-term targets; histological healing in ulcerative colitis is not a formal target. The ACG 2025 guideline recommends treating to endoscopic improvement (Mayo endoscopic subscore 0 or 1) to increase the likelihood of sustained steroid-free remission and to prevent hospitalization and surgery, and the ECCO 2026 guideline describes treat-to-target beyond steroid-free clinical remission as not yet conclusively validated. In the pooled ABTECT induction trials, the placebo-adjusted clinical remission rate at Week 8 with obefazimod 50 mg was 16.4%. In the ABTECT maintenance trial, clinical remission at Week 44 was 50.8% with 25 mg and 51.3% with 50 mg against 10.4% with placebo among 580 induction responders. At week 8 of induction, 37% of participants on 50 mg reported no bowel urgency against 18.1% on placebo. In Study 108, 68% (88/130) of participants were in clinical remission at week 144 after dose reduction to 25 mg. These obefazimod results come from press releases and congress presentations; no peer-reviewed full report of ABTECT has been published.